Sponsor content
342 result(s) found, displaying 91 to 100
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
Prescription medicine registrationActive ingredients: sodium zirconium cyclosilicate hydrate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RILAST RAPIHALER budesonide / formoterol fumarate dihydrate 100/3 pressurised metered dose inhaler.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RILAST RAPIHALER budesonide / formoterol fumarate dihydrate 200/6 pressurised metered dose inhaler.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CALQUENCE acalabrutinib (as maleate) 100 mg film-coated tablet blister pack.
-
Designation or determinationProvisional determination
-
Australian Public Assessment Report (AusPAR)Imjudo (tremelimumab) is approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian Public Assessment Report (AusPAR)Imfinzi (Durvalumab) has been approved for the treatment of unresectable hepatocellular carcinoma.